BR9815285A - Vetores alfavìrus para vacina de paramixovìrus - Google Patents

Vetores alfavìrus para vacina de paramixovìrus

Info

Publication number
BR9815285A
BR9815285A BR9815285-8A BR9815285A BR9815285A BR 9815285 A BR9815285 A BR 9815285A BR 9815285 A BR9815285 A BR 9815285A BR 9815285 A BR9815285 A BR 9815285A
Authority
BR
Brazil
Prior art keywords
dna
protein
vectors
rsv
alphavirus
Prior art date
Application number
BR9815285-8A
Other languages
English (en)
Inventor
Mark Parrington
Xiaomao Li
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of BR9815285A publication Critical patent/BR9815285A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"VETORES ALFAVìRUS PARA VACINA DE PARAMIXOVìRUS".Um vetor de DNA compreende uma primeira seq³ência de DNAcomplementar a pelo menos parte de um genoma de RNA dealfavírus e tendo o complemento de regiões de replicaçãogenómica de DNA de alfavírus completas, e uma segundaseq³ência de DNA que codifica uma proteína de paramixovírus,particularmente uma proteína de fusão de vírus sincicialrespiratório (VSR F) ou um fragmento de proteína F de VSR quegera anticorpos que reagem especificamente com a proteína F deVSR, as primeira e segunda seq³ências de DNA estando sobcontrole de transcrição de um promotor, preferivelmente, umpromotor de citomegalovírus, o qual pode incluir ìntron A. Taisvetores também contêm uma seq³ência de nucleotídeo adicionallocalizada entre a seq³ência promotora e a seq³ência de alfavíruspara incrementar a habilidade imunoprotetora da proteína F deVSR quando expressa in vivo. Tais vetores de DNA podem serusados para imunizar um hospedeiro contra doença causada porinfecção por VSR ou outro paramixovírus, incluindo um hospedeirohumano, por administração a este, e podem ser formulados comocomposições imunogênicas com transportadoresfarmaceuticamente aceitáveis para tais objetivos. Tais vetorestambém podem ser utilizados para produzir anticorpos paradetecção de infecção por VSR ou por outro paramixovírus em umaamostra.
BR9815285-8A 1997-11-14 1998-11-13 Vetores alfavìrus para vacina de paramixovìrus BR9815285A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6579197P 1997-11-14 1997-11-14
PCT/CA1998/001064 WO1999025858A1 (en) 1997-11-14 1998-11-13 Alphavirus vectors for paramyxovirus vaccines

Publications (1)

Publication Number Publication Date
BR9815285A true BR9815285A (pt) 2001-11-13

Family

ID=22065142

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815285-8A BR9815285A (pt) 1997-11-14 1998-11-13 Vetores alfavìrus para vacina de paramixovìrus

Country Status (7)

Country Link
US (2) US20030180257A1 (pt)
EP (1) EP1034289A1 (pt)
JP (1) JP2002512003A (pt)
AU (1) AU749345B2 (pt)
BR (1) BR9815285A (pt)
CA (1) CA2309826A1 (pt)
WO (1) WO1999025858A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
JP2002512003A (ja) 1997-11-14 2002-04-23 コノート ラボラトリーズ リミテッド パラミキソウイルスワクチンのためのアルファウイルスベクター
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
CA2383519A1 (en) * 1999-08-31 2001-03-08 The University Of North Carolina At Chapel Hill Antibody dependent enhancement (ade) of alphavirus infection
CA2410948C (en) 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
BRPI0411099A (pt) * 2003-06-05 2006-07-18 Wyeth Corp composições imunogênicas que compreendem os vetores de replicon do vìrus da encefalite eqüina venezuelana e antìgenos de proteìnas de paramixovìrus
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
EP1766034B1 (en) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
BRPI0916443A2 (pt) 2008-07-16 2017-10-31 Inst Res Biomedicine anticorpos de neutralização de citomegalovírus humanos e uso dos mesmos
US20120128713A1 (en) * 2009-03-16 2012-05-24 Sanofi Pasteur Limited Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE105334T1 (de) 1988-04-22 1994-05-15 Upjohn Co Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
JP2002512003A (ja) 1997-11-14 2002-04-23 コノート ラボラトリーズ リミテッド パラミキソウイルスワクチンのためのアルファウイルスベクター
FR2781323B1 (fr) 1998-07-16 2000-08-18 Alsthom Cge Alcatel Procede de transmission dans des fenetres successives

Also Published As

Publication number Publication date
US6475780B1 (en) 2002-11-05
US20030180257A1 (en) 2003-09-25
EP1034289A1 (en) 2000-09-13
AU749345B2 (en) 2002-06-27
AU1139099A (en) 1999-06-07
CA2309826A1 (en) 1999-05-27
WO1999025858A1 (en) 1999-05-27
JP2002512003A (ja) 2002-04-23

Similar Documents

Publication Publication Date Title
BR9815642A (pt) Vetor sequência de dna mutante, transcrição linear de rna de um vetor, composição e método para produzir uma vacina de rna de vìrus sincicial respiratório
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
JP2004511201A5 (pt)
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
BR9911163A (pt) Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo
ATE419368T1 (de) System zum transfer und zur expression von heterologen genen ins knochenmark in vivo
WO1999029871A3 (fr) Sequences de circovirus associe a la maladie de l'amaigrissement du porcelet (map)
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
BR9712138A (pt) Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
TR200401186T4 (tr) Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları.
BR9814204A (pt) "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"
WO1999008706A8 (en) Recombinant porcine adenovirus vector
BR9811592A (pt) Oxidase de citocinina
BR9803960A (pt) Gene de desidrogenase de d-sorbitol.
BR9609871A (pt) Vacina de urease recombinante multimérica
EP0775746A3 (en) Coccidiosis poultry vaccine
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
WO1999058639A3 (en) Structural proteins of fish pancreatic disease virus and uses thereof
WO2003008571A3 (es) Cadenas quiméricas codificantes para proteínas inductoras de efectos contra virus
BR0012020A (pt) Proteìna, e, dna
AU686000B2 (en) Infectious peritonitis vaccine
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
AU5153196A (en) Diagnostic and therapeutic system for Crohn's Disease and colitia ulcerosa
BR0003561A (pt) Processo para a preparação fermentativa de produtos metabólicos e para as sequências de nucleotìdeos codificando para o gene sod
NZ511168A (en) Recombinant CELO virus and CELO virus DNA

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO - DE ACORDO COM O ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.